logo

Endocyte, Inc. (ECYT)



Trade ECYT now with
  Date
  Headline
7/31/2018 8:13:10 AM Endocyte Q2 Net Loss $11.6 Mln Or $0.17/Shr Vs Loss $11.7 Mln Or $0.28/Shr Last Year
7/9/2018 9:28:01 AM Endocyte, ITM Announce Long-Term Supply Agreement For No-Carrier-Added Lutetium-177
6/22/2018 8:03:31 AM Endocyte Says Multiple Presentations Related To Endocyte’s PSMA-617 Radioligand Therapy Will Be Presented At SNMMI
6/5/2018 8:05:35 AM Endocyte Announces Enrollment Of First Patient In Phase 3 VISION Trial Of 177Lu-PSMA-617 In Prostate Cancer
5/9/2018 2:28:03 PM Wedbush Is Increasing Endocyte, Inc. (ECYT) FY18 Estimate To -0.69 From -0.98
5/9/2018 2:27:45 PM Wedbush Is Increasing Endocyte, Inc. (ECYT) Q2 18 Estimate To -0.15 From -0.24
5/9/2018 8:10:19 AM Endocyte Announces The Lancet Oncology Publication Of Phase 2 Data From Prostate Cancer Trial Of (177)Lu-PSMA-617
5/9/2018 8:10:04 AM Endocyte Q1 Net Loss $8.6 Mln Or $0.16/Shr Vs Net Loss $11.5 Mln Or $0.27/Shr Last Year
2/28/2018 9:19:58 AM Endocyte Prices Public Offering Of 17.86 Mln Shares At $4.20 Per Share
2/27/2018 4:02:37 PM Endocyte Appoints Patrick Machado To Its Board Of Directors
2/26/2018 2:09:32 PM Wedbush Is Cutting Endocyte, Inc. (ECYT) 2018 Estimate To -0.98 From -0.79
2/26/2018 2:09:15 PM Wedbush Is Cutting Endocyte, Inc. (ECYT) 4Q18 Estimate To -0.28 From -0.23
2/26/2018 2:08:53 PM Wedbush Is Lowering Endocyte, Inc. (ECYT) 3Q18 Estimate To -0.26 From -0.21
2/26/2018 2:08:38 PM Wedbush Is Cutting Endocyte, Inc. (ECYT) 2Q18 Estimate To -0.24 From -0.19